Daclizumab (Zenapax) shows promise in MS

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Daclizumab (Zenapax) shows promise in MS

Postby MSUK » Mon Oct 24, 2011 2:13 am

Image


Treatment with daclizumab (Zenapax), an investigational monoclonal antibody drug, cut annualized relapse rates in half among patients with early relapsing-remitting multiple sclerosis (MS) in a placebo-controlled trial, a researcher said here.

Annualized relapse rates averaged 0.21 and 0.23 with two different dosage levels of daclizumab, compared with 0.46 for patients put on placebo in the one-year, 600-patient trial known as SELECT (both P<0.001), reported Gavin Giovannoni, MD, of Queen Mary University in London.

The drug also showed significant efficacy in a host of secondary outcomes, including physical function, disability progression, and MRI lesion burden, he said at the joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1502
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2180
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service